Allergan motion to compel texts denied in US trade secret row over Botox
MLex Summary: A special master assigned to discovery disputes between Allergan and rival Revance Therapeutics denied Allergan's motion to compel discovery, holding that Revance does not have "control" over its employees'...To view the full article, register now.
Already a subscriber? Click here to view full article